RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter has maintained an 'Outperform' rating on 4D Molecular Therapeutics (NASDAQ: FDMT) and increased the price target from $32 to $35. This adjustment reflects a positive outlook on the company's performance.